AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cboe Global Markets
CBOE
|
+$1.07B |
| 2 |
Applovin
APP
|
+$455M |
| 3 |
Broadcom
AVGO
|
+$450M |
| 4 |
AXON
Axon Enterprise
AXON
|
+$442M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$440M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$1.6B |
| 2 |
Walt Disney
DIS
|
+$795M |
| 3 |
Idexx Laboratories
IDXX
|
+$692M |
| 4 |
Zoetis
ZTS
|
+$640M |
| 5 |
Microsoft
MSFT
|
+$615M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.02% |
| 2 | Healthcare | 12.31% |
| 3 | Consumer Discretionary | 11.7% |
| 4 | Financials | 11.01% |
| 5 | Communication Services | 9.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
Newmark Group
NMRK
$2.69B
| $2.12M | ﹤0.01% |
165,687
-12,100
| -7% | -$179K |
|
1927
UroGen Pharma
URGN
$2B
| $2.12M | ﹤0.01% |
199,259
+175,859
| +752% | +$2.11M |
|
1928
Neumora Therapeutics
NMRA
$308M
| $2.12M | ﹤0.01% |
199,947
-22,930
| -10% | -$275K |
|
1929
Tarsus Pharmaceuticals
TARS
$2.53B
| $2.12M | ﹤0.01% |
38,250
| – | – |
|
1930
La-Z-Boy
LZB
$1.65B
| $2.12M | ﹤0.01% |
48,545
+301
| +0.6% | +$12.7K |
|
1931
Kinetik
KNTK
$3.74B
| $2.1M | ﹤0.01% |
37,078
+78
| +0.2% | +$4.22K |
|
1932
Norwood Financial Corp
NWFL
$368M
| $2.09M | ﹤0.01% |
+76,910
| New | +$2.24M |
|
1933
OneSpaWorld
OSW
$2.65B
| $2.09M | ﹤0.01% |
105,130
| – | – |
|
1934
Fortrea Holdings
FTRE
$1.95B
| $2.09M | ﹤0.01% |
111,845
+57,879
| +107% | +$1.13M |
|
1935
WesBanco
WSBC
$4B
| $2.08M | ﹤0.01% |
64,046
-62,727
| -49% | -$2.08M |
|
1936
LeMaitre Vascular
LMAT
$2.39B
| $2.08M | ﹤0.01% |
22,584
+1,287
| +6% | +$124K |
|
1937
Nelnet
NNI
$4.93B
| $2.08M | ﹤0.01% |
19,437
-33,433
| -63% | -$3.7M |
|
1938
Embecta
EMBC
$218M
| $2.07M | ﹤0.01% |
100,456
-15,768
| -14% | -$258K |
|
1939
Rogers Corp
ROG
$2.11B
| $2.07M | ﹤0.01% |
20,413
-24
| -0.1% | -$2.5K |
|
1940
BioCryst Pharmaceuticals
BCRX
$2.45B
| $2.07M | ﹤0.01% |
275,390
-400
| -0.1% | -$3.04K |
|
1941
Edgewise Therapeutics
EWTX
$4.32B
| $2.06M | ﹤0.01% |
77,260
+1,300
| +2% | +$41.4K |
|
1942
DigitalBridge
DBRG
$2.93B
| $2.06M | ﹤0.01% |
182,694
-4,544,918
| -96% | -$61.1M |
|
1943
Atlanta Braves Holdings Series B
BATRK
$3.27B
| $2.05M | ﹤0.01% |
53,501
| – | – |
|
1944
City Holding Co
CHCO
$2.04B
| $2.04M | ﹤0.01% |
17,253
| – | – |
|
1945
Lemonade
LMND
$3.75B
| $2.04M | ﹤0.01% |
55,555
-13,330
| -19% | -$426K |
|
1946
Trinity Capital Inc.
TRIN
$1.59B
| $2.04M | ﹤0.01% |
140,825
-8,000
| -5% | -$113K |
|
1947
PCB Bancorp
PCB
$392M
| $2.03M | ﹤0.01% |
100,399
+10
| +0% | +$200 |
|
1948
Enterprise Financial Services Corp
EFSC
$2.41B
| $2.03M | ﹤0.01% |
35,943
-3,450
| -9% | -$193K |
|
1949
AvePoint
AVPT
$2.78B
| $2.03M | ﹤0.01% |
122,654
-33,451
| -21% | -$508K |
|
1950
Inspire Medical Systems
INSP
$1.47B
| $2.02M | ﹤0.01% |
10,918
-106
| -1% | -$20.6K |
|
Similar funds
AllianceBernstein's Q4 2024 Portfolio in Review
As of Q4 2024, AllianceBernstein held 3,298 positions worth $295B, down 1% from $298B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Trading was light in Q4 2024: portfolio turnover was 4.4%. AllianceBernstein opened 67 new positions and exited 77, leaving the 3,298-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- AllianceBernstein's largest Q4 2024 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 2,000,000 shares worth $157M.
- AllianceBernstein added most to Cboe Global Markets in Q4 2024, an estimated $1.07B increase.
- AllianceBernstein's biggest Q4 2024 reduction was Vertex Pharmaceuticals, cutting an estimated $1.6B.
- AllianceBernstein fully exited iShares US Treasury Bond ETF in Q4 2024, selling an estimated $176M.
- AllianceBernstein's ten largest holdings make up 30% of its $295B portfolio in Q4 2024.
- AllianceBernstein opened 67 new positions and closed 77 in Q4 2024.
- AllianceBernstein's portfolio value fell 1% quarter-over-quarter to $295B.
Based on AllianceBernstein's 13F filing for Q4 2024, filed 12 Feb 2025.